Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thommen, D. S. & Schumacher, T. N. T Cell dysfunction in cancer. Cancer Cell 33, 547–562 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mognol, G. P. et al. Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells. Proc. Natl Acad. Sci. USA 114, E2776–E2785 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crawford, A. et al. Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection. Immunity 40, 289–302 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sen, D. R. et al. The epigenetic landscape of T cell exhaustion. Science 354, 1165–1169 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wherry, E. J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670–684 (2007).

Article  CAS  PubMed  Google Scholar 

Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160–1165 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghoneim, H. E. et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell 170, 142–157.e19 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blackburn, S. D., Shin, H., Freeman, G. J. & Wherry, E. J. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade. Proc. Natl Acad. Sci. USA 105, 15016–15021 (2008).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topper, M. J. et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 171, 1284–1300.e21 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li, X. et al. Increased IFNγ+ T cells are responsible for the clinical responses of low-dose DNA-demethylating agent decitabine antitumor therapy. Clin. Cancer Res. 23, 6031–6043 (2017).

Article  CAS  PubMed  Google Scholar 

Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R. & Baylin, S. B. The emerging role of epigenetic therapeutics in immuno-oncology. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-019-0266-5 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Aspeslagh, S., Morel, D., Soria, J. C. & Postel-Vinay, S. Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Ann. Oncol. 29, 812–824 (2018).

Article  CAS  PubMed  Google Scholar 

Tien, F. M., Lu, H. H., Lin, S. Y. & Tsai, H. C. Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. J. Biomed. Sci. 30, 3 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Abdel-Hakeem, M. S. et al. Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. Nat. Immunol. 22, 1008–1019 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Almeida, J. R. et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204, 2473–2485 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiu, Y. L. et al. Sprouty-2 regulates HIV-specific T cell polyfunctionality. J. Clin. Invest. 124, 198–208 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding, Z. C. et al. Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 120, 2229–2239 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weng, R. R. et al. Epigenetic modulation of immune synaptic-cytoskeletal networks potentiates γδ T cell-mediated cytotoxicity in lung cancer. Nat. Commun. 12, 2163 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li, X. et al. Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. J. Clin. Invest. 133, e165673 (2023).

Kagoya, Y. et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J. Clin. Invest. 126, 3479–3494 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Kong, W. et al. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. J. Clin. Invest. 131, e145459 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Zhu, H. et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 16, 2829–2837 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chee, J. et al. Impaired T cell proliferation by ex vivo BET-inhibition impedes adoptive immunotherapy in a murine melanoma model. Epigenetics 15, 134–144 (2020).

Article  PubMed  Google Scholar 

Georgiev, P. et al. BET bromodomain inhibition suppresses human T cell function. Immunohorizons 3, 294–305 (2019).

Article  CAS  PubMed  Google Scholar 

Gibbons, H. R. et al. Bromodomain inhibitor JQ1 reversibly blocks IFN-γ production. Sci. Rep. 9, 10280 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Huang, Z. Y. et al. Single-cell analysis of diverse immune phenotypes in malignant pleural effusion. Nat. Commun. 12, 6690 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Principe, N. et al. Malignant pleural effusions—a window into local anti-tumor T cell immunity? Front. Oncol. 11, 672747 (2021).

Buggert, M. et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. 10, e1004251 (2014).

Paley, M. A. et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220–1225 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ananieva, E. A., Powell, J. D. & Hutson, S. M. Leucine metabolism in T cell activation: mTOR signaling and beyond. Adv. Nutr. 7, 798S–805S (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma, C. et al. Upregulated ethanolamine phospholipid synthesis via selenoprotein I is required for effective metabolic reprogramming during T cell activation. Mol. Metab. 47, 101170 (2021).

Article  CAS  PubMed